source
- FDA approves Lipfendra, first oral PCSK9 inhibitor, to lower LDL cholesterol in adultsThe U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral inhibitor of the PCSK9 protein, for use as an adjunct to diet and exercise in adults with high cholesterol,…
- Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit ForecastAbbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…